Last reviewed · How we verify
Beetroot
Beetroot is a Small molecule drug developed by David Travis Thomas. It is currently in Phase 2 development. Also known as: BEETELITE™ NeO Shot.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Beetroot |
|---|---|
| Also known as | BEETELITE™ NeO Shot |
| Sponsor | David Travis Thomas |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Nitric Oxide (NO) and Endothelial Dysfunction in Women With PTSD (NA)
- Beetroot Beverage and Repeated Sprint Power Output During RAST (NA)
- Beetroot Juice: A Natural Boost for Cardiovascular Health in Postmenopausal Women? (NA)
- Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study (EARLY_PHASE1)
- Effects of Beetroot Extract on Blood Pressure and Exercise in Hypertensive Older Women (NA)
- Inorganic Nitrates in Intermediate High-risk Pulmonary Embolism (NA)
- Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men (NA)
- Use of Beetroot Juice to Protect Against Postoperative Ileus Following Colorectal Surgery: BEET IT Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beetroot CI brief — competitive landscape report
- Beetroot updates RSS · CI watch RSS
- David Travis Thomas portfolio CI
Frequently asked questions about Beetroot
What is Beetroot?
Who makes Beetroot?
Is Beetroot also known as anything else?
What development phase is Beetroot in?
Related
- Manufacturer: David Travis Thomas — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: BEETELITE™ NeO Shot
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing